Resolvin D1 attenuates inflammation in lipopolysaccharide-induced acute lung injury through a process involving the PPARγ/NF-κB pathway

Table 1 Differential cell counts (expressed as cells × 10⁴) in BALF from mice subjected to LPS-induced ALI following different treatments

Treatment group	Time after LPS induction of ALI
	6 h			12 h			24 h
	Macrophages	Neutrophils	Lymphocytes	Macrophages	Neutrophils	Lymphocytes	Macrophages	Neutrophils	Lymphocytes
Saline	15.43 ± 6.80	0.03 ± 0.04	0.55 ± 0.42	22.10 ± 7.10	0.07 ± 0.07	0.50 ± 0.66	25.25 ± 7.99	0.22 ± 0.05	0.53 ± 0.03
RvD1 (600 ng)	21.25 ± 8.89	0.42 ± 0.72	1.00 ± 0.31	22.34 ± 3.70	0.33 ± 0.42	1.33 ± 0.61	28.44 ± 4.29	0.18 ± 0.19	1.71 ± 1.10
LPS	15.07 ± 3.35	128.89 ± 6.45	2.37 ± 0.69	15.83 ± 4.71	162.73 ± 4.00	3.11 ± 1.75	20.74 ± 3.71	193.61 ± 7.65	2.65 ± 1.64
RvD1 (300 ng) + LPS	11.71 ± 3.62	99.42 ± 8.10*#	1.87 ± 2.15	17.41 ± 2.52	121.07 ± 8.46*#	2.19 ± 0.60	20.24 ± 2.78	155.77 ± 5.70*#	2.99 ± 0.46
RvD1 (600 ng) + LPS	10.70 ± 1.23	63.33 ± 2.09*	2.97 ± 2.27	10.39 ± 1.41	81.38 ± 8.00*	3.23 ± 1.38	14.50 ± 1.77	120.59 ± 9.59*	3.91 ± 1.59
GW9662	17.90 ± 4.40	0.21 ± 0.36	0.57 ± 0.34	26.48 ± 10.81	0.48 ± 0.66	1.71 ± 0.98	26.19 ± 12.49	0.30 ± 0.32	1.51 ± 1.22
GW9662 + RvD1 (600 ng) + LPS	13.02 ± 2.61	99.59 ± 7.15*#	2.72 ± 1.43	15.52 ± 0.71	113.52 ± 16.19*#	3.29 ± 0.58	14.15 ± 1.46	152.59 ± 2.91*#	3.60 ± 1.26

Data are mean ± SD, n = 3. BALF, bronchoalveolar lavage fluid. RvD1, resolvin D1. * p < 0.05 in comparison with the LPS group at each time point. # p < 0.05 in comparison with the RvD1 (600 ng) + LPS group at each time point.

ISSN: 1465-993X